JP2023058678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023058678A5 JP2023058678A5 JP2023022208A JP2023022208A JP2023058678A5 JP 2023058678 A5 JP2023058678 A5 JP 2023058678A5 JP 2023022208 A JP2023022208 A JP 2023022208A JP 2023022208 A JP2023022208 A JP 2023022208A JP 2023058678 A5 JP2023058678 A5 JP 2023058678A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- less
- active agent
- suspension
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 239000013543 active substance Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000000725 suspension Substances 0.000 claims 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 5
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 claims 5
- 229960004502 levodopa Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000002002 slurry Substances 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- 239000000375 suspending agent Substances 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000005587 bubbling Effects 0.000 claims 2
- 229960004205 carbidopa Drugs 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- LQQFFJFGLSKYIR-UHFFFAOYSA-N 3,4-dihydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C(O)=C1 LQQFFJFGLSKYIR-UHFFFAOYSA-N 0.000 claims 1
- IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 229940123973 Oxygen scavenger Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- DZAUWHJDUNRCTF-UHFFFAOYSA-N dihydrocaffeic acid Natural products OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024107963A JP2024129122A (ja) | 2015-01-20 | 2024-07-04 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105565P | 2015-01-20 | 2015-01-20 | |
| US62/105,565 | 2015-01-20 | ||
| US201562272922P | 2015-12-30 | 2015-12-30 | |
| US62/272,922 | 2015-12-30 | ||
| JP2020214665A JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020214665A Division JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024107963A Division JP2024129122A (ja) | 2015-01-20 | 2024-07-04 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023058678A JP2023058678A (ja) | 2023-04-25 |
| JP2023058678A5 true JP2023058678A5 (enExample) | 2023-11-07 |
Family
ID=55410198
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556790A Pending JP2018503686A (ja) | 2015-01-20 | 2016-01-20 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2020214665A Active JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2023022208A Ceased JP2023058678A (ja) | 2015-01-20 | 2023-02-16 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2024107963A Pending JP2024129122A (ja) | 2015-01-20 | 2024-07-04 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556790A Pending JP2018503686A (ja) | 2015-01-20 | 2016-01-20 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2020214665A Active JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024107963A Pending JP2024129122A (ja) | 2015-01-20 | 2024-07-04 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10117843B2 (enExample) |
| EP (2) | EP3247330A1 (enExample) |
| JP (4) | JP2018503686A (enExample) |
| KR (1) | KR20170103967A (enExample) |
| CN (2) | CN107427463A (enExample) |
| AU (1) | AU2016209420B2 (enExample) |
| BR (1) | BR112017015613B1 (enExample) |
| CA (1) | CA2974203A1 (enExample) |
| IL (1) | IL253487A0 (enExample) |
| MA (1) | MA41377A (enExample) |
| MX (1) | MX384262B (enExample) |
| PH (1) | PH12017501304A1 (enExample) |
| RU (1) | RU2017129375A (enExample) |
| SG (1) | SG11201705964YA (enExample) |
| TW (1) | TW201639556A (enExample) |
| WO (1) | WO2016118556A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2965379A1 (en) | 2014-10-21 | 2016-04-28 | Abbvie Inc. | Carbidopa and l-dopa prodrugs and methods of use |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| MX2019000849A (es) * | 2016-07-20 | 2019-09-13 | Abbvie Inc | Gel intestinal de levodopa y carbidopa y metodos de uso. |
| AU2019379806B2 (en) | 2018-11-15 | 2025-08-14 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN119510592A (zh) * | 2023-08-22 | 2025-02-25 | 上海汉都医药科技有限公司 | 一种含有卡比多巴的药物中肼含量的检测方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| ATE118216T1 (de) | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| CN101636145B (zh) | 2006-05-31 | 2014-04-23 | 雅培产品有限公司 | 长期24小时经肠给予左旋多巴/卡比多巴 |
| EP3777839A1 (en) | 2009-05-19 | 2021-02-17 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| NZ610911A (en) * | 2010-11-15 | 2015-02-27 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| BR112013014304A2 (pt) * | 2010-12-10 | 2016-07-19 | Synagile Corp | composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão |
| US8765189B2 (en) | 2011-05-13 | 2014-07-01 | Howmedica Osteonic Corp. | Organophosphorous and multivalent metal compound compositions and methods |
| WO2013033453A2 (en) | 2011-08-31 | 2013-03-07 | Abbott Laboratories | Sealing arrangement for syringe |
| US20160022573A1 (en) | 2013-03-13 | 2016-01-28 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| JP6538063B2 (ja) | 2013-11-05 | 2019-07-03 | シンアジャル コーポレイション | 口を介する連続的薬物送達のためのデバイスおよび方法 |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
-
2016
- 2016-01-19 MA MA041377A patent/MA41377A/fr unknown
- 2016-01-20 KR KR1020177022953A patent/KR20170103967A/ko not_active Withdrawn
- 2016-01-20 CA CA2974203A patent/CA2974203A1/en not_active Abandoned
- 2016-01-20 AU AU2016209420A patent/AU2016209420B2/en active Active
- 2016-01-20 US US15/001,392 patent/US10117843B2/en active Active
- 2016-01-20 RU RU2017129375A patent/RU2017129375A/ru not_active Application Discontinuation
- 2016-01-20 CN CN201680016049.3A patent/CN107427463A/zh active Pending
- 2016-01-20 BR BR112017015613-0A patent/BR112017015613B1/pt not_active IP Right Cessation
- 2016-01-20 MX MX2017009325A patent/MX384262B/es unknown
- 2016-01-20 CN CN202310053820.6A patent/CN116036064A/zh active Pending
- 2016-01-20 EP EP16706041.7A patent/EP3247330A1/en not_active Withdrawn
- 2016-01-20 SG SG11201705964YA patent/SG11201705964YA/en unknown
- 2016-01-20 JP JP2017556790A patent/JP2018503686A/ja active Pending
- 2016-01-20 EP EP24194552.6A patent/EP4470611A3/en active Pending
- 2016-01-20 TW TW105101753A patent/TW201639556A/zh unknown
- 2016-01-20 WO PCT/US2016/014005 patent/WO2016118556A1/en not_active Ceased
-
2017
- 2017-07-14 IL IL253487A patent/IL253487A0/en unknown
- 2017-07-18 PH PH12017501304A patent/PH12017501304A1/en unknown
-
2018
- 2018-10-16 US US16/161,940 patent/US20190142777A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,892 patent/US20210046029A1/en not_active Abandoned
- 2020-12-24 JP JP2020214665A patent/JP7232235B2/ja active Active
-
2023
- 2023-02-16 JP JP2023022208A patent/JP2023058678A/ja not_active Ceased
-
2024
- 2024-07-04 JP JP2024107963A patent/JP2024129122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023058678A5 (enExample) | ||
| JP2022105175A5 (enExample) | ||
| CN1222279C (zh) | 缓释型生物粘附性阴道凝胶剂型 | |
| JP2024129122A5 (enExample) | ||
| CN101132801B (zh) | 用于制备二氧化碳外用制剂的组合物 | |
| JP2019501215A (ja) | 局所皮膜形成スプレー | |
| RU2017129375A (ru) | Интестинальный гель на основе леводопы и карбидопы и способы его применения | |
| GB0814302D0 (en) | Compounds and methods | |
| JP2008535867A5 (enExample) | ||
| JP2022166217A5 (enExample) | ||
| CN102065896A (zh) | 消炎镇痛外用剂 | |
| EP3845247A1 (en) | Application of amino acid nutrient, and pharmaceutical composition including amino acid nutrient | |
| JP2022166217A (ja) | レボドパ及びカルビドパ腸管ゲル、並びに使用方法 | |
| CN105412040B (zh) | 一种硝苯地平控释片及其制备方法 | |
| JP2018500365A5 (enExample) | ||
| MX2025007901A (es) | Formulación inyectable que comprende un agente biofarmacéutico y un copolímero basado en poliacrilamida | |
| CN111346081A (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| CN112516159B (zh) | 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用 | |
| WO2019170912A1 (en) | Bioresorbable controlled-release compositions with sting modulating molecules | |
| RU2010129409A (ru) | Способ лечения псороптоза кроликов и отодектоза плотоядных животных | |
| CN101181230A (zh) | 一种治疗实体肿瘤的雌二醇氮芥缓释植入剂 | |
| JP2001522885A (ja) | 血中ヒスタミンレベルを上昇させるためのヒスタミンの使用 | |
| JPS60208917A (ja) | Ａｒｄｓおよび多器官不全治療、予防におけるプロスタグランジンの使用 | |
| CN116763718A (zh) | 一种紫杉醇纳米晶温敏凝胶及其制备方法和其应用 | |
| EP1872798B1 (en) | Intestinal absorptive anti-tumor agent |